Drugs / AZD9592
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06366451 | May 2024 → Mar 2026 | head and neck squamous cell carcinoma | Presage Biosciences | Completed | No outcome recorded |
| Phase 0 | NCT04541108 | Jul 2021 → Dec 2031 expected | cancer | Presage Biosciences | Active not recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05647122 | Dec 2022 → Jun 2026 overdue | colorectal neoplasm, head and neck neoplasm, non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | Results AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗
This is the Company’s first bispecific ADC to enter the clinic and shows a promising efficacy and safety profile in preclinical models, with evidence for DNA damage dependent tumour cell death as the mechanism of action. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-14 | AstraZeneca | AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR astrazeneca.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD9592 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04541108 ↗ |
| Route | Other | “Intratumoral microdose injection by the CIVO device.” NCT06366451 ↗ |